ArticleThe oncologist2013
Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients.
Article in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report.AIDS research and therapy · 2023Article
- Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV.PloS one · 2023Observational
- Review
- Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience.Cancers · 2021Article
- A Brazilian university hospital position regarding transplantation criteria for HIV-positive patients according to the current literature.Clinics (Sao Paulo, Brazil) · 2019Review
- Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review.Oncotarget · 2018Review
- Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.Oncotarget · 2017Review
- Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.World journal of gastroenterology · 2016Review
- Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.Frontiers in pharmacology · 2016Review
- Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection.Frontiers in pharmacology · 2016Review
- Role of liver transplantation in human immunodeficiency virus positive patients.World journal of gastroenterology · 2015Review
- Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era.World journal of virology · 2015Review
- Clinical characteristics of human immunodeficiency virus patients being referred for liver transplant evaluation: a descriptive cohort study.Transplant infectious disease : an official journal of the Transplantation Society · 2015Article
- Pros and cons of liver transplantation in human immunodeficiency virus infected recipients.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of our work is to assess the clinical outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC) in HIV-coinfected patients. This is a multicenter study involving three Italian transplant centers in northern Italy: University of Modena, University of Bologna, and University of Udine. PATIENTS AND
methodsWe compared 30 HIV-positive patients affected by HCC who underwent LT with 125 HIV-uninfected patients who received the same treatment from September 2004 to June 2009. At listing, there were no differences between HIV-infected and -uninfected patients regarding HCC features. Patients outside the University of California, San Francisco criteria (UCSF) were considered eligible for LT if a down-staging program permitted a reduction of tumor burden.
resultsHIV-infected patients were younger, they were more frequently anti-HCV positive, and a higher number of HIV-infected patients presented a coinfection HBV-HCV. Pre-LT treatments (liver resection and or locoregional treatments) were similar between the two groups. Histological characteristics of the tumor were similar in patients with and without HIV infection. No differences were observed in terms of overall survival and HCC recurrence rates.
conclusionLT for HCC is a feasible procedure and the presence of HIV does not particularly affect the post-LT outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.